Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 77

2.

In situ vaccination with CD204 gene-silenced dendritic cell, not unmodified dendritic cell, enhances radiation therapy of prostate cancer.

Guo C, Yi H, Yu X, Zuo D, Qian J, Yang G, Foster BA, Subjeck JR, Sun X, Mikkelsen RB, Fisher PB, Wang XY.

Mol Cancer Ther. 2012 Nov;11(11):2331-41. doi: 10.1158/1535-7163.MCT-12-0164. Epub 2012 Aug 15.

3.

Pattern recognition receptors of innate immunity and their application to tumor immunotherapy.

Seya T, Shime H, Ebihara T, Oshiumi H, Matsumoto M.

Cancer Sci. 2010 Feb;101(2):313-20. doi: 10.1111/j.1349-7006.2009.01442.x. Epub 2009 Nov 17. Review.

4.

Prostate cancer: advances in immunotherapy.

Hurwitz AA, Yanover P, Markowitz M, Allison JP, Kwon ED.

BioDrugs. 2003;17(2):131-8. Review.

PMID:
12641491
5.

Clearance of apoptotic cells is not impaired in mouse embryos deficient in class A scavenger receptor types I and II (CD204).

Komohara Y, Terasaki Y, Kaikita K, Suzuki H, Kodama T, Takeya M.

Dev Dyn. 2005 Jan;232(1):67-74.

6.

TRANCE- and CD40 ligand-matured dendritic cells reveal MHC class I-restricted T cells specific for autologous tumor in late-stage ovarian cancer patients.

Schlienger K, Chu CS, Woo EY, Rivers PM, Toll AJ, Hudson B, Maus MV, Riley JL, Choi Y, Coukos G, Kaiser LR, Rubin SC, Levine BL, Carroll RG, June CH.

Clin Cancer Res. 2003 Apr;9(4):1517-27.

7.

Advances in specific immunotherapy for prostate cancer.

Kiessling A, Füssel S, Wehner R, Bachmann M, Wirth MP, Rieber EP, Schmitz M.

Eur Urol. 2008 Apr;53(4):694-708. Epub 2007 Nov 26. Review.

PMID:
18061335
8.

Scavenger receptor class A type I/II (CD204) null mice fail to develop fibrosis following silica exposure.

Beamer CA, Holian A.

Am J Physiol Lung Cell Mol Physiol. 2005 Aug;289(2):L186-95. Epub 2005 Apr 22.

9.

Combined natural killer T-cell based immunotherapy eradicates established tumors in mice.

Teng MW, Westwood JA, Darcy PK, Sharkey J, Tsuji M, Franck RW, Porcelli SA, Besra GS, Takeda K, Yagita H, Kershaw MH, Smyth MJ.

Cancer Res. 2007 Aug 1;67(15):7495-504.

10.

The critical role of type-1 innate and acquired immunity in tumor immunotherapy.

Ikeda H, Chamoto K, Tsuji T, Suzuki Y, Wakita D, Takeshima T, Nishimura T.

Cancer Sci. 2004 Sep;95(9):697-703. Review.

11.

Improvement of a dendritic cell-based therapeutic cancer vaccine with components of Toxoplasma gondii.

Motamedi M, Arab S, Moazzeni SM, Khamis Abadi M, Hadjati J.

Clin Vaccine Immunol. 2009 Oct;16(10):1393-8. doi: 10.1128/CVI.00199-09. Epub 2009 Aug 5.

12.

CRTAM receptor engagement by Necl-2 on tumor cells triggers cell death of activated Vγ9Vδ2 T cells.

Dessarthe B, Thedrez A, Latouche JB, Cabillic F, Drouet A, Daniel P, de La Pintière CT, Catros V, Toutirais O.

J Immunol. 2013 May 1;190(9):4868-76. doi: 10.4049/jimmunol.1202596. Epub 2013 Mar 25.

13.

Enhancement of immunologic tumor regression by intratumoral administration of dendritic cells in combination with cryoablative tumor pretreatment and Bacillus Calmette-Guerin cell wall skeleton stimulation.

Udagawa M, Kudo-Saito C, Hasegawa G, Yano K, Yamamoto A, Yaguchi M, Toda M, Azuma I, Iwai T, Kawakami Y.

Clin Cancer Res. 2006 Dec 15;12(24):7465-75.

14.

Immune checkpoint blockade immunotherapy to activate anti-tumour T-cell immunity.

Ramsay AG.

Br J Haematol. 2013 Aug;162(3):313-25. doi: 10.1111/bjh.12380. Epub 2013 May 21. Review.

PMID:
23691926
15.

Preclinical pharmacokinetics, tissue distribution, and antitumor activity of a folate-hapten conjugate-targeted immunotherapy in hapten-immunized mice.

Lu Y, Xu LC, Parker N, Westrick E, Reddy JA, Vetzel M, Low PS, Leamon CP.

Mol Cancer Ther. 2006 Dec;5(12):3258-67.

16.

Interleukin-10-induced T cell unresponsiveness can be reversed by dendritic cell stimulation.

Chen ML, Wang FH, Lee PK, Lin CM.

Immunol Lett. 2001 Jan 1;75(2):91-6.

PMID:
11137131
17.

Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity.

Fotin-Mleczek M, Duchardt KM, Lorenz C, Pfeiffer R, Ojkić-Zrna S, Probst J, Kallen KJ.

J Immunother. 2011 Jan;34(1):1-15. doi: 10.1097/CJI.0b013e3181f7dbe8.

PMID:
21150709
18.

Mistletoe lectin has a shiga toxin-like structure and should be combined with other Toll-like receptor ligands in cancer therapy.

Maletzki C, Linnebacher M, Savai R, Hobohm U.

Cancer Immunol Immunother. 2013 Aug;62(8):1283-92. doi: 10.1007/s00262-013-1455-1. Epub 2013 Jul 6.

PMID:
23832140
19.

Killer dendritic cells and their potential role in immunotherapy.

Ullrich E, Chaput N, Zitvogel L.

Horm Metab Res. 2008 Feb;40(2):75-81. doi: 10.1055/s-2007-1022554. Review.

PMID:
18283624
20.

[Innate immunity: structure and function of TLRs].

Delneste Y, Beauvillain C, Jeannin P.

Med Sci (Paris). 2007 Jan;23(1):67-73. French.

Items per page

Supplemental Content

Write to the Help Desk